Altered CSF orexin and α-synuclein levels in dementia patients

Journal of Alzheimer's Disease

Volumn 29, Issue 1, 2012, Pages 125-132

  Wennström, Malin ^a   Londos, Elisabet ^a   Minthon, Lennart ^a   Nielsen, Henrietta M ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alpha synuclein; Alzheimer's disease; biomarker; dementia with Lewy bodies; orexin

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; OREXIN; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MALE; NARCOLEPSY; NERVE DEGENERATION; PRIORITY JOURNAL; SEX DIFFERENCE; WESTERN BLOTTING;

EID: 84858136734     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-111655     Document Type: Article

References (46)

1. Hauw JJ, Hausser-Hauw C, De Girolami U, Hasboun D, Seilhean D (2011) Neuropathology of sleep disorders: A review. J Neuropathol Exp Neurol 70, 243-252.
2. De la Herran-Arita AK, Guerra-Crespo M, Drucker-Colin R (2011) Narcolepsy and orexins: An example of progress in sleep research. Front Neurol 2, 26.
3. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS, 2nd, Frankel WN, van den Pol AN, Bloom FE, Gautvik KM, Sutcliffe JG (1998) The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 95, 322-327. (Pubitemid 28103952)
4. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H,Williams SC, Richarson JA,Kozlowski GP,Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M (1998) Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 1 page following 696.
5. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, Kilduff TS (1998) Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18, 9996-10015. (Pubitemid 28543775)
6. Overeem S, Mignot E, van Dijk JG, Lammers GJ (2001) Narcolepsy: Clinical features, newpathophysiologic insights, and future perspectives. J Clin Neurophysiol 18, 78-105. (Pubitemid 32549906)
7. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM (2000) Reduced number of hypocretin neurons in human narcolepsy. Neuron 27, 469-474.
8. Nishino S, Ripley B, Overeem S, Nevsimalova S, Lammers GJ, Vankova J, Okun M, Rogers W, Brooks S, Mignot E (2001) Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 50, 381-388. (Pubitemid 32848741)
9. Friedman LF, Zeitzer JM, Lin L, Hoff D, Mignot E, Peskind ER,Yesavage JA(2007) In Alzheimer disease, increasedwake fragmentation found in those with lower hypocretin-1. Neurology 68, 793-794. (Pubitemid 46667913)
10. Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG, Lammers GJ, Swaab DF (2007) Hypocretin (orexin) loss in Parkinson's disease. Brain 130, 1577-1585. (Pubitemid 47355929)
11. Fronczek R, van Geest S, Frolich M, Overeem S, Roelandse FW, Lammers GJ, Swaab DF (2011) Hypocretin (orexin) loss in Alzheimer's disease. Neurobiol Aging, doi:10.1016/j.neurobiolaging.2011.03.014.
12. Lessig S, Ubhi K, Galasko D, Adame A, Pham E, Remidios K, Chang M, Hansen LA, Masliah E (2010) Reduced hypocretin (orexin) levels in dementia with Lewy bodies. Neuroreport 21, 756-760.
13. Thannickal TC, Lai YY, Siegel JM (2007) Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130, 1586-1595. (Pubitemid 47355933)
14. Baumann CR, Dauvilliers Y, Mignot E, Bassetti CL (2004) Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness. Eur Neurol 52, 73-76. (Pubitemid 39274286)
15. Yasui K, Inoue Y, Kanbayashi T, Nomura T, Kusumi M, Nakashima K (2006) CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 250, 120-123. (Pubitemid 44665944)
16. Compta Y, Santamaria J, Ratti L, Tolosa E, Iranzo A, Munoz E, Valldeoriola F, Casamitjana R, Rios J, Marti MJ (2009) Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. Brain 132, 3308-3317.
17. Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM (2009) Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 326, 1005-1007.
18. Grossberg AJ, Zhu X, Leinninger GM, Levasseur PR, Braun TP, Myers MG, Jr. Marks DL (2011) Inflammation-induced lethargy is mediated by suppression of orexin neuron activity. J Neurosci 31, 11376-11386.
19. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL,Veerhuis R,Walker D,Webster S,Wegrzyniak B,Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421. (Pubitemid 30349107)
20. Mackenzie IR (2000) Activated microglia in dementia with Lewy bodies. Neurology 55, 132-134.
21. Tansey M, Goldberg M (2010) Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37, 510-518.
22. Nielsen HM, Londos E, Minthon L, Janciauskiene SM (2007) Soluble adhesion molecules and angiotensin-converting enzyme in dementia. Neurobiol Dis 26, 27-35. (Pubitemid 46436485)
23. Nielsen HM, Minthon L, Londos E, Blennow K, Miranda E, Perez J, Crowther DC, Lomas DA, Janciauskiene SM (2007) Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology 69, 1569-1579. (Pubitemid 350287140)
24. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34, 939-944. (Pubitemid 14076461)
25. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J,Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, deVos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 47, 1113-1124. (Pubitemid 26374873)
26. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
27. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, Qureshi MM, Locascio JJ, Schlossmacher MG, El-Agnaf OM (2006) Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 349, 162-166. (Pubitemid 44331776)
28. Johren O, Neidert SJ, Kummer M, Dominiak P (2002) Sexually dimorphic expression of prepro-orexin mRNA in the rat hypothalamus. Peptides 23, 1177-1180. (Pubitemid 34786309)
29. Silveyra P, Cataldi NI, Lux-Lantos VA, Libertun C (2010) Role of orexins in the hypothalamic-pituitary-ovarian relationships. Acta Physiol (Oxf) 198, 355-360.
30. Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JR, Dartigues JF, Kragh-Sorensen P, Baldereschi M, Brayne C, Lobo A, Martinez-Lage JM, Stijnen T, Hofman A (1999) Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology 53, 1992-1997.
31. Gao S, Hendrie HC, Hall KS, Hui S (1998) The relationships between age, sex, and the incidence of dementia and Alzheimer disease: A meta-analysis. Arch Gen Psychiatry 55, 809-815. (Pubitemid 28413043)
32. Nelson PT, Schmitt FA, Jicha GA, Kryscio RJ, Abner EL, Smith CD, Van Eldik LJ, Markesbery WR (2010) Association between male gender and cortical Lewy body pathology in large autopsy series. J Neurol 257, 1875-1881.
33. Silva A, Andersen ML, De Mello MT, Bittencourt LR, Peruzzo D, Tufik S (2008) Gender and age differences in polysomnography findings and sleep complaints of patients referred to a sleep laboratory. Braz J Med Biol Res 41, 1067-1075.
34. MacGowan SH, Wilcock GK, Scott M (1998) Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. Int J Geriatr Psychiatry 13, 625-630. (Pubitemid 28441962)
35. Wattmo C, Wallin AK, Londos E, Minthon L (2011) Predictors of long-term cognitive outcome in Alzheimer's disease. Alzheimers Res Ther 3, 23.
36. Brownell SE, Conti B (2010) Age- and gender-specific changes of hypocretin immunopositive neurons in C57Bl/6 mice. Neurosci Lett 472, 29-32.
37. Gerashchenko D, Murillo-Rodriguez E, Lin L, Xu M, Hallett L, Nishino S, Mignot E, Shiromani PJ (2003) Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol 184, 1010-1016. (Pubitemid 38182831)
38. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, Ng J, Schulz-Schaeffer W, Kretzschmar HA, McLean PJ, Trenkwalder C, Sarracino DA, Vonsattel JP, Locascio JJ, El-Agnaf OM, Schlossmacher MG (2008) Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213, 315-325.
39. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, Zhang J (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133, 713-726.
40. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
41. Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, Blennow K, Zetterberg H (2009) Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders a marker of synapse loss?. Neurosci Lett 450, 332-335.
42. Waxman EA, Giasson BI (2011) Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci 31, 7604-7618.
43. Jensen PH, Hager H, Nielsen MS, Hojrup P, Gliemann J, Jakes R (1999) Alpha-synuclein binds to tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem 274, 25481-25489. (Pubitemid 29418572)
44. Kawakami F, Suzuki M, Shimada N, Kagiya G, Ohta E, Tamura K, Maruyama H, Ichikawa T (2011) Stimulatory effect of alpha-synuclein on the tau-phosphorylation by GSK-3beta. FEBS J 278, 4895-4904.
45. Licastro F, Mallory M, Hansen LA, Masliah E (1998) Increased levels of alpha-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype. J Neuroimmunol 88, 105-110. (Pubitemid 28342910)
46. Licastro F, Parnetti L, Morini MC, Davis LJ, Cucinotta D, Gaiti A, Senin U (1995) Acute phase reactant alpha 1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer disease. Alzheimer Dis Assoc Disord 9, 112-118.